Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants

Hye Won Kwak; Hyo Jung Park; Seo Yeon Jung; Eun Young Oh; Sang In Park; Yeonhwa Kim; Hyeong Jun Park; Sohyun Park; You Jin Kim; Hae Li Ko; Jung Ah Lee; Hyeran Won; Yun Ho Hwang; Seo Yeon Kim; Se Eun Kim; Seoung Eun Bae; Minhyuk Yoon; Jae Ouk Kim; Manki Song; Su Jeen Lee; Ki Weon Seo; Kunse Lee; Dokeun Kim; Hun Kim; Sang Myeong Lee; So Hee Hong; Jae Hwan Nam

doi:10.1016/j.vaccine.2023.02.005

Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants

Hye Won Kwak, Hyo Jung Park, Seo Yeon Jung, Eun Young Oh, Sang In Park, Yeonhwa Kim, Hyeong Jun Park, Sohyun Park, You Jin Kim, Hae Li Ko, Jung Ah Lee, Hyeran Won, Yun Ho Hwang, Seo Yeon Kim, Se Eun Kim, Seoung Eun Bae, Minhyuk Yoon, Jae Ouk Kim, Manki Song, Su Jeen LeeKi Weon Seo, Kunse Lee, Dokeun Kim, Hun Kim, Sang Myeong Lee, So Hee Hong, Jae Hwan Nam

Department of Microbiology

Research output: Contribution to journal › Article › peer-review

Abstract

Owing to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants, the development of effective and safe vaccines has become a priority. The measles virus (MeV) vaccine is an attractive vaccine platform as it has been administered to children for more than 40 years in over 100 countries. In this study, we developed a recombinant MeV expressing the full-length SARS-CoV-2 spike protein (rMeV-S) and tested its efficacy using mouse and hamster models. In hCD46Tg mice, two-dose rMeV-S vaccination induced higher Th1 secretion and humoral responses than one-dose vaccination. Interestingly, neutralizing antibodies induced by one-dose and two-dose rMeV-S immunization effectively blocked the entry of the α, β, γ, and δ variants of SARS-CoV-2. Furthermore, two-dose rMeV-S immunization provided complete protection against SARS-CoV-2 in the hamster model. These results suggest the potential of rMeV-S as a vaccine candidate for targeting SARS-CoV-2 and its variants.

Original language	English
Pages (from-to)	1892-1901
Number of pages	10
Journal	Vaccine
Volume	41
Issue number	11
DOIs	https://doi.org/10.1016/j.vaccine.2023.02.005
State	Published - 10 Mar 2023

Keywords

Measles virus vector
Neutralizing antibody
SARS-CoV-2

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2023.02.005

Cite this

Kwak, H. W., Park, H. J., Jung, S. Y., Oh, E. Y., Park, S. I., Kim, Y., Park, H. J., Park, S., Kim, Y. J., Ko, H. L., Lee, J. A., Won, H., Hwang, Y. H., Kim, S. Y., Kim, S. E., Bae, S. E., Yoon, M., Kim, J. O., Song, M., ... Nam, J. H. (2023). Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants. Vaccine, 41(11), 1892-1901. https://doi.org/10.1016/j.vaccine.2023.02.005

@article{c8a23fe347d340ec96766ecd9ccb54c0,

title = "Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants",

abstract = "Owing to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants, the development of effective and safe vaccines has become a priority. The measles virus (MeV) vaccine is an attractive vaccine platform as it has been administered to children for more than 40 years in over 100 countries. In this study, we developed a recombinant MeV expressing the full-length SARS-CoV-2 spike protein (rMeV-S) and tested its efficacy using mouse and hamster models. In hCD46Tg mice, two-dose rMeV-S vaccination induced higher Th1 secretion and humoral responses than one-dose vaccination. Interestingly, neutralizing antibodies induced by one-dose and two-dose rMeV-S immunization effectively blocked the entry of the α, β, γ, and δ variants of SARS-CoV-2. Furthermore, two-dose rMeV-S immunization provided complete protection against SARS-CoV-2 in the hamster model. These results suggest the potential of rMeV-S as a vaccine candidate for targeting SARS-CoV-2 and its variants.",

keywords = "Measles virus vector, Neutralizing antibody, SARS-CoV-2",

author = "Kwak, {Hye Won} and Park, {Hyo Jung} and Jung, {Seo Yeon} and Oh, {Eun Young} and Park, {Sang In} and Yeonhwa Kim and Park, {Hyeong Jun} and Sohyun Park and Kim, {You Jin} and Ko, {Hae Li} and Lee, {Jung Ah} and Hyeran Won and Hwang, {Yun Ho} and Kim, {Seo Yeon} and Kim, {Se Eun} and Bae, {Seoung Eun} and Minhyuk Yoon and Kim, {Jae Ouk} and Manki Song and Lee, {Su Jeen} and Seo, {Ki Weon} and Kunse Lee and Dokeun Kim and Hun Kim and Lee, {Sang Myeong} and Hong, {So Hee} and Nam, {Jae Hwan}",

note = "Funding Information: This work was supported by the Research Investment for Global Health Technology Fund [RIGHT Fund]; SK Bioscience [grant numbers M-2020-D0731-0001, M-2020-D0732-0003]; the Korea Health Industry Development Institute (KHIDI) funded by the Ministry for Health and Welfare, Republic of Korea [grant number KHIDIHV21C0020020021]; the National Research Foundation (NRF) funded by the Ministry of Science and ICT, Republic of Korea [grant number 2021M3E5E3080558]; and the Brain Korea 21 Plus Program. Publisher Copyright: {\textcopyright} 2023 Elsevier Ltd",

year = "2023",

month = mar,

day = "10",

doi = "10.1016/j.vaccine.2023.02.005",

language = "English",

volume = "41",

pages = "1892--1901",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "11",

}

Kwak, HW, Park, HJ, Jung, SY, Oh, EY, Park, SI, Kim, Y, Park, HJ, Park, S, Kim, YJ, Ko, HL, Lee, JA, Won, H, Hwang, YH, Kim, SY, Kim, SE, Bae, SE, Yoon, M, Kim, JO, Song, M, Lee, SJ, Seo, KW, Lee, K, Kim, D, Kim, H, Lee, SM, Hong, SH & Nam, JH 2023, 'Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants', Vaccine, vol. 41, no. 11, pp. 1892-1901. https://doi.org/10.1016/j.vaccine.2023.02.005

TY - JOUR

T1 - Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants

AU - Kwak, Hye Won

AU - Park, Hyo Jung

AU - Jung, Seo Yeon

AU - Oh, Eun Young

AU - Park, Sang In

AU - Kim, Yeonhwa

AU - Park, Hyeong Jun

AU - Park, Sohyun

AU - Kim, You Jin

AU - Ko, Hae Li

AU - Lee, Jung Ah

AU - Won, Hyeran

AU - Hwang, Yun Ho

AU - Kim, Seo Yeon

AU - Kim, Se Eun

AU - Bae, Seoung Eun

AU - Yoon, Minhyuk

AU - Kim, Jae Ouk

AU - Song, Manki

AU - Lee, Su Jeen

AU - Seo, Ki Weon

AU - Lee, Kunse

AU - Kim, Dokeun

AU - Kim, Hun

AU - Lee, Sang Myeong

AU - Hong, So Hee

AU - Nam, Jae Hwan

N1 - Funding Information: This work was supported by the Research Investment for Global Health Technology Fund [RIGHT Fund]; SK Bioscience [grant numbers M-2020-D0731-0001, M-2020-D0732-0003]; the Korea Health Industry Development Institute (KHIDI) funded by the Ministry for Health and Welfare, Republic of Korea [grant number KHIDIHV21C0020020021]; the National Research Foundation (NRF) funded by the Ministry of Science and ICT, Republic of Korea [grant number 2021M3E5E3080558]; and the Brain Korea 21 Plus Program. Publisher Copyright: © 2023 Elsevier Ltd

PY - 2023/3/10

Y1 - 2023/3/10

N2 - Owing to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants, the development of effective and safe vaccines has become a priority. The measles virus (MeV) vaccine is an attractive vaccine platform as it has been administered to children for more than 40 years in over 100 countries. In this study, we developed a recombinant MeV expressing the full-length SARS-CoV-2 spike protein (rMeV-S) and tested its efficacy using mouse and hamster models. In hCD46Tg mice, two-dose rMeV-S vaccination induced higher Th1 secretion and humoral responses than one-dose vaccination. Interestingly, neutralizing antibodies induced by one-dose and two-dose rMeV-S immunization effectively blocked the entry of the α, β, γ, and δ variants of SARS-CoV-2. Furthermore, two-dose rMeV-S immunization provided complete protection against SARS-CoV-2 in the hamster model. These results suggest the potential of rMeV-S as a vaccine candidate for targeting SARS-CoV-2 and its variants.

AB - Owing to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants, the development of effective and safe vaccines has become a priority. The measles virus (MeV) vaccine is an attractive vaccine platform as it has been administered to children for more than 40 years in over 100 countries. In this study, we developed a recombinant MeV expressing the full-length SARS-CoV-2 spike protein (rMeV-S) and tested its efficacy using mouse and hamster models. In hCD46Tg mice, two-dose rMeV-S vaccination induced higher Th1 secretion and humoral responses than one-dose vaccination. Interestingly, neutralizing antibodies induced by one-dose and two-dose rMeV-S immunization effectively blocked the entry of the α, β, γ, and δ variants of SARS-CoV-2. Furthermore, two-dose rMeV-S immunization provided complete protection against SARS-CoV-2 in the hamster model. These results suggest the potential of rMeV-S as a vaccine candidate for targeting SARS-CoV-2 and its variants.

KW - Measles virus vector

KW - Neutralizing antibody

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85148341677&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2023.02.005

DO - 10.1016/j.vaccine.2023.02.005

M3 - Article

C2 - 36792434

AN - SCOPUS:85148341677

SN - 0264-410X

VL - 41

SP - 1892

EP - 1901

JO - Vaccine

JF - Vaccine

IS - 11

ER -

Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this